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Co-culture of prion-infected cells with uninfected
target cells has recently been found to lead to rapid
and efficient transmission of infectivity to the target
cells by a process that is dependent on direct cell
contact.
The prion protein (PrP) appears to be the sole
causative agent of the fatal neurodegenerative spongi-
form encephalopathies, such as Creutzfeldt–Jakob
(CJD) disease in humans and scrapie and bovine
spongiform encephalopathy (BSE) in animals [1]. A
key, possibly unique, feature of prion diseases is their
transmissibility from one organism to another.
Although it has been known for many years that prion
diseases are transmissible, the molecular mechanisms
involved in transmission from one cell to another have
remained unclear. Now Kanu et al. [2], using prion
infected and uninfected cell lines, have shown that cell
contact is required for the effective transmission of the
disease.
During disease progression, the normal cellular form
of PrP (PrPC) undergoes a conformational change
from a predominantly α-helical form to an abnormal
isoform (PrPSc) which has mainly β-sheet structure.
Although the structure of PrPC has been determined
[3–5], the structure of PrPSc awaits elucidation. PrPSc
can, however, be distinguished experimentally from
PrPC by its relative resistance to protease digestion.
PrPC is a glycosylated cell surface protein, attached to
the outer leaflet of the plasma membrane via a
glycosyl-phosphatidylinositol (GPI) anchor [6–8]. Cells
expressing PrPC can be converted to stable produc-
tion of PrPSc upon exposure to subcellular prepara-
tions containing PrPSc, such as homogenates from the
brains of prion-infected animals [9]. The extent of
infection of cells in culture by such subcellular prepa-
rations is usually poor, however, and the molecular
mechanisms involved in the initial conversion of the
cellular PrPC by the exogenous PrPSc are not fully
understood.
The work of Kanu et al. [2] — reported in this issue
of Current Biology — now provides an insight into
these processes. These authors used a cell line (SMB)
that was originally derived from a culture of mouse
brain infected with the Chandler strain of mouse
scrapie. It had earlier been reported [10] that these
infected cells could be cured of infectivity and PrPSc
production by growth in the presence of pentosan
sulphate, and that the resulting PS cell line was
readily re-infected by exposure to homogenates of
scrapie-infected mouse brain. Kanu et al. [2] have
now cocultured the infected SMB cells producing
PrPSc with the uninfected PS cells producing PrPC
(Figure 1). To distinguish between the SMB cells and
the target PS cells, the latter were transfected with the
neomycin gene. 
After several days, the SMB cells were selectively
killed by addition of the antibiotic G418, leaving the PS
cells intact. Following several passages in medium
containing antibiotic, the presence of PrPSc in the PS
cells was examined by Western blot analysis following
protease digestion. The PS target cells were now
found to be producing PrPSc (Figure 1). That this
abnormal form of the protein was being synthesised
de novo, and did not just represent protein carried
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Figure 1. Two possible routes for the transmission of PrPSc
between neighbouring cells.
SMB cells expressing PrPSc (red triangles) are cocultured with
uninfected PS target cells expressing PrPC (blue circles). On the
left, PrPSc on the SMB cell acts in trans on the PrPC on the PS
cell converting the latter to PrPSc (blue triangles). On the right,
PrPSc jumps from the SMB cell to the PS cell, where it incorpo-
rates into the plasma membrane and in cis converts PrPC in the
target cell membrane to PrPSc. In both cases, further molecules
of PrPC are converted to PrPSc in the target cell in cis through
template assisted and/or seeded polymerisation models [19].
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over from the original SMB cells, was shown by the
incorporation of radiolabelled methionine. Thus, Kanu
et al. [2] concluded that the target PS cells had been
converted to stable production of PrPSc by coculture
with the SMB cells — that is, the PS cells had been
infected.
Two possible mechanisms can be put forward 
for this cell-mediated conversion of PrPC by PrPSc
(Figure 1). One is that PrPSc on the SMB cell acts in
trans on PrPC on an adjacent target cell, converting it
to PrPSc. Once a few molecules of PrPC have been
converted to PrPSc on the target cell, further mole-
cules are converted in cis — that is, on the same cell
surface — by the newly formed PrPSc molecules.
Alternatively, intact PrPSc, including its complete GPI
anchor, may jump from the SMB cell to the target cell,
a phenomenon that has been well documented for
GPI-anchored proteins [11,12]. Once in the target cell
membrane, the PrPSc from the original infected cell
acts in cis on the target cell plasma membrane to
convert the PrPC to further molecules of PrPSc.
However, the release of PrPSc — or some other
diffusible signal — from the SMB cells into the
medium in either a soluble or aggregated form, which
then binds to or is taken up by the target cells,
appears to be ruled out by a number of observations
[2]. Exposure of PS cells to conditioned medium from
SMB cells failed to cause the PS cells to produce
PrPSc, and even culture of the cells in close proximity,
but separated by a porous membrane, failed to result
in effective infection of the PS cells. Further evidence
for the requirement for contact between the SMB and
PS cells came from the observation that aldehyde-
fixed SMB cells can convert the PS target cells to
stable production of PrPSc, albeit at a somewhat
reduced level as compared with unfixed SMB cells.
These data imply that infection is dependent on cell
contact, possibly explaining why prion diseases prop-
agate at a much slower rate than would be expected
for a mechanism involving diffusible extracellular
forms of PrP. Such a scenario fits with the relatively
slow time course of prion infection in vivo [13].
The cell-free conversion of PrPC to PrPSc is
relatively inefficient, requiring the presence of denat-
urants, detergents or chaperones [14,15]. In contrast,
conversion of a dish of PS target cells by the SMB
cells required some 2,500-fold less PrPSc than was
required for conversion of the PS cells by a brain
homogenate [2]. This suggests that presentation of
PrPSc attached to a membrane is more effective for
converting PrPC in adjacent cells than PrPSc pre-
sented in ‘solution’. This agrees with a recent study
[16] in which the presence of a GPI anchor on PrP
allowed for more efficient conversion to a PrPSc-like
form in a cell-free assay, and with earlier studies
[17,18] showing that localisation of PrPC in the cell
membrane via its GPI anchor is important in the for-
mation of protease-resistant PrP in scrapie-infected
tissue culture cells.
In conclusion, not only will the cell contact infection
system reported by Kanu et al. [2] be useful for
identifying other factors involved in the PrPC-to-PrPSc
conversion process, but the system also lends itself to
the screening of potential compounds that could
block disease transmission by interfering with the
interaction between PrPSc on the infected cell and
PrPC on neighbouring uninfected target cells.
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